中信证券股份有限公司 关于苏州纳微科技股份有限公司 2024 年度募集资金存放与使用情况的核查意见 中信证券股份有限公司（以下简称"中信证券"或"保荐人"）作为苏州 纳微科技股份有限公司（以下简称"纳微科技"或"公司"）首次公开发行并 在科创板上市、向特定对象发行股票的持续督导保荐人，根据《证券发行上市 保荐业务管理办法》《上市公司监管指引第2号——上市公司募集资金管理和使 用的监管要求》《上海证券交易所科创板上市公司自律监管指引第1号——规范 运作》《上海证券交易所科创板股票上市规则》《科创板上市公司持续监管办 法（试行）》等有关规定，对纳微科技2024年度募集资金的存放和使用情况进 行了专项核查，核查情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 1、2021年首次公开发行股票实际募集资金情况 公司经中国证券监督管理委员会证监许可[2021]1395号文核准，于2021年6 月向社会公开发行人民币普通股（A股）4,400万股，每股发行价为8.07元，应 募集资金总额为人民币35,508万元，根据有关规定扣除发行费用4,714.39万元后， 实际募集资金金额为30,793.61万元。 ...

审计报告 苏州纳微科技股份有限公司 容诚审字[2025]200Z1703号 容诚会计师事务所(特殊普通合伙 ) 中国·北京 目 录 | 序号 | 内 | 容 | | 页码 | | --- | --- | --- | --- | --- | | 1 | 审计报告 | | 1-6 | | | 2 | 合并资产负债表 | | 1 | | | 3 | 合并利润表 | | 2 | | | 4 | 合并现金流量表 | | 3 | | | 5 | 合并所有者权益变动表 | | 4-5 | | | 6 | 母公司资产负债表 | | 6 | | | 7 | 母公司利润表 | | 7 | | | 8 | 母公司现金流量表 | | 8 | | | 9 | 母公司所有者权益变动表 | | 9-10 | | | 10 | 财务报表附注 | | 11 - | 132 | 容诚会计师事务所（特殊普通合伙） 总所：北京市西城区阜成门外大街 22 号 1 幢 10 层 1001-1 至 1001-26（100037） TEL:010-6600 1391 FAX:010-6600 1392 E-mail:bj@rsmchina.com.cn h ...

纳微科技公告，公司通过股权转让及增资方式，取得苏州纳信科技有限公司51.25%股权，投资总额 1576.92万元。交易完成后，纳信科技注册资本由2000万元增至3076.92万元。纳信科技主营溶剂回收膜 材料的研发、生产及销售。此次投资有助于公司为医药客户提供更全面的分离纯化整体解决方案，增强 公司在生物医药产业的竞争力和品牌影响力。 ...

国泰海通主要观点如下： 政策受益，科研制药上游是战略新兴产业自主可控的重要组成部分 智通财经获悉，国泰海通发布研报称，科研制药上游作为战略新兴产业自主可控的重要组成部分，正迎 来政策与市场的双重驱动。国家层面持续出台支持政策，包括《"十四五"生物经济发展规划》要求提升 产业链安全水平，科技部明确"高端产品研发自主化"目标，叠加进口品牌受关税成本上升影响，具备自 主创新能力的国产企业迎来替代窗口期。重点推荐泰坦科技(688133.SH)、阿拉丁(688179.SH)、纳微科 技(688690.SH)等核心标的。 风险提示：关税地缘政治风险、全球医药研发景气度风险、创新药鼓励扶持政策不达预期风险。 中国市场正以庞大的人口基数与快速增长的生物医药需求逐渐成为生命科学产业的新兴市场，未来几年 中国生命科学制品市场规模将快速增长，生命科学制品的高端市场长期由欧美企业主导，该行认为，国 产替代空间依然巨大。在国产替代的大趋势下，具备自主创新研发能力、能够提供性能与进口产品相 似、甚至优于进口产品的企业将在激烈的市场竞争中脱颖而出。 若进口品牌受关税影响成本上升，国产品牌性价比有望进一步凸显 根据默克、珀金埃尔默等进口品牌 ...

Group 1 - The core viewpoint is that the upstream pharmaceutical research and development sector is a crucial part of the strategic emerging industry, benefiting from both policy and market drivers [1][2] - The Chinese government has introduced a series of supportive policies for the biopharmaceutical industry, emphasizing the need for domestic substitution and enhancing the safety and stability of the supply chain [2][3] - The report highlights key recommended stocks such as Titan Technology (688133.SH), Aladdin (688179.SH), and Nawei Technology (688690.SH) as core targets for investment [1] Group 2 - The domestic innovation-driven substitution is expected to rapidly increase the domestic substitution rate in the biopharmaceutical market, which is becoming a new emerging market due to its large population and growing demand [3] - The high-end market for life science products has been dominated by European and American companies, but there is significant potential for domestic alternatives to emerge [3] - The cost pressure on imported brands due to tariffs is expected to create a favorable environment for domestic brands, enhancing their competitiveness [4]

Core Viewpoint - The lawsuit involving Suzhou Nawei Technology Co., Ltd. is currently in the appeal stage, with both the plaintiff and defendants contesting the first-instance judgment. The company is a third party in the case and does not bear any liability, ensuring that its operations and profits remain unaffected by the litigation [2][11]. Summary by Sections Lawsuit Background - On December 5, 2022, the company received a civil complaint from Han Han, who is seeking to confirm a claim of 51,556,500 yuan for a share of 5,698,350 yuan held by Suzhou Nabai [3]. - The lawsuit has evolved, with Han Han modifying his claims on August 31, 2023, to seek 38,273,600 yuan for a share of 4,230,240 yuan and additional compensation for 2,656,580 shares [4]. - By May 31, 2024, Han Han introduced an alternative claim for 302,596,775.52 yuan in damages, along with interest calculations based on LPR standards [5]. Court Decisions and Appeals - On August 12, 2024, the court ruled that Suzhou Nabai must pay Han Han 18,994,500 yuan, while other claims were dismissed [6]. - In September 2024, both parties filed appeals against the judgment, with Suzhou Nabai seeking to overturn the ruling and Han Han requesting full support for his claims [6][8]. Recent Developments - To mitigate the impact of the lawsuit on the company's stock incentive plans, Suzhou Nabai and its chairman, Dr. Jiang Biwang, submitted a request to the Jiangsu Provincial High Court to replace frozen assets with equivalent shares [9]. - The court has since ruled to freeze 5,112,900 shares held by Dr. Jiang while lifting the asset preservation measures on Suzhou Nabai's partnership interests [9][10]. Impact on Company Operations - The company maintains that the lawsuit will not affect its operational stability or governance, as it is involved as a third party and is not liable for any claims [11]. - The freezing of 1.27% of the company's shares held by Dr. Jiang will not alter the control structure of the company, ensuring that its management remains stable [11].

证券代码：688690 证券简称：纳微科技 公告编号：2025-005 苏州纳微科技股份有限公司 关于涉及诉讼进展的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 1、2022 年 12 月 5 日，公司收到苏州市中级人民法院送达的关于韩寒起诉公 司、苏州纳百及公司董事长江必旺博士等三方的《民事起诉书》等相关材料。韩 案件所处的诉讼阶段：原告、被告就一审判决分别提起上诉 原告：韩寒 寒起诉要求（1）确认以 51,556,500 元的对价享有苏州纳百持有苏州纳研的财产 份额 5,698,350 元；（2）要求公司向韩寒支付针对 2,656,580 股激励股份的收购 价款 122,909,330.28 元，并承担资金占用损失。 具 体 内 容 详 见 公 司 于 2022 年 12 月 7 日 在 上 海 证 券 交 易 所 网 站 （www.sse.com.cn）披露的《苏州纳微科技股份有限公司关于涉及诉讼的公告》 （公告编号：2022-100）。 被告一：苏州纳百管理咨询有限公司（以下简称"苏州纳百" ...

Financial Performance - The company achieved total operating revenue of RMB 782.65 million in 2024, representing a year-on-year growth of 33.36%[4] - Operating profit increased to RMB 94.50 million, up 44.94% compared to the previous year, while total profit rose to RMB 93.57 million, a 43.15% increase[4] - Net profit attributable to shareholders reached RMB 81.11 million, reflecting an 18.29% growth year-on-year, with a significant increase of 104.11% in net profit after deducting non-recurring gains and losses, totaling RMB 64.47 million[7] Gross Margin and Revenue Composition - The company's gross margin for 2024 was 70.24%, a decrease of approximately 7.65 percentage points from the previous year, primarily due to an increase in the proportion of instrument product revenue[6] - The core business of chromatography fillers and chromatography media generated approximately RMB 451 million in revenue, growing about 10.20% year-on-year[6] Research and Development - Research and development investment amounted to RMB 177 million, a 9.47% increase from the previous year, accounting for 22.61% of total operating revenue[7] Cash Flow and Assets - The net cash flow from operating activities was approximately RMB 132 million, representing a year-on-year growth of about 5.11%[7] - The total assets at the end of the reporting period were RMB 2.31 billion, an increase of 8.67% from the beginning of the period[4] Equity and Investments - The weighted average return on equity increased to 4.74%, up 0.51 percentage points from the previous year[4] - The company acquired a partial stake in Fuli Instruments, which contributed RMB 153.54 million to the consolidated revenue starting from March 2024[8]

证券代码：688690 证券简称：纳微科技 公告编号：2025-003 苏州纳微科技股份有限公司 关于股份回购实施结果暨股份变动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 | 回购方案首次披露日 | 2024/1/31，由公司实际控制人、董事长江必旺博 | | --- | --- | | | 士提议 | | 回购方案实施期限 | 自董事会审议通过后 12 个月内 | | 预计回购金额 | 万元~10,000 万元 5,000 | | 回购价格上限 | 35 元/股 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 实际回购股数 | 306.6622 万股 | | 实际回购股数占总股本比例 | 0.76% | | 实际回购金额 | 6,099.45 万元 | | 实际回购价格区间 | 15.52 元/股~22.18 元/股 | 重要内容提示： 一、 回购审批情况和回购方案内容 （四）本次实施股份回购使用的资金为自有资金 ...